Results 51 to 60 of about 27,150 (219)

Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study [PDF]

, 2019
To assess the effectiveness of the treatment with high dosage of corticosteroids (CCSs), as first-line therapy, in inducing remission in naïve Adult-onset Still's disease (AOSD) patients compared with low dosage of CCSs, after 6 months.
Berardicurti O., Carubbi F., Ciccia F., Cipriani P., Giacomelli R., Guggino G., Liakouli V., Ruscitti P.   +7 more
core   +1 more source

Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study [PDF]

European Journal of Preventive Cardiology, 2019
Aims Novel therapies are needed for recurrent pericarditis, particularly when corticosteroid dependent and colchicine resistant. Based on limited data, interleukin-1 blockade with anakinra may be beneficial. The aim of this multicentre registry was to evaluate the broader effectiveness and safety of anakinra in a ‘real world’ population.
Imazio M., Andreis A., De Ferrari G. M., Cremer P. C., Mardigyan V., Maestroni S., Luis S. A., Lopalco G., Emmi G., Lotan D., Marcolongo R., Lazaros G., De Biasio M., Cantarini L., Dagna L., Cercek A. C., Pivetta E., Varma B., Berkson L., Tombetti E., Iannone F., Prisco D., Caforio A. L. P., Vassilopoulos D., Tousoulis D., De Luca G., Giustetto C., Rinaldi M., Oh J. K., Klein A. L., Brucato A., Adler Y.   +31 more
openaire   +8 more sources

Recommendations for the Use of Disease‐Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review

Arthritis Care &Research, EarlyView.
Objective Autoimmune rheumatic diseases commonly affect individuals of childbearing age, with historically increased adverse pregnancy outcomes in this group. The advent of disease‐modifying antirheumatic drugs (DMARDs) has fostered more suitable conditions for pregnancy; however, this is accompanied by challenges in ensuring safe use in reproductive ...
Athena Chin, Alice Terrett, Mihye Kwon, Samuel Whittle, Catherine Hill   +4 more
wiley   +1 more source

Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis

European Journal of Medical Research, 2023
Background At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen ...
Karolina Dahms, Agata Mikolajewska, Kelly Ansems, Maria-Inti Metzendorf, Carina Benstoem, Miriam Stegemann   +5 more
doaj   +1 more source

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet, Bhatia, Ravi, Campbell, Victoria L., Chu, Su, Gaal, Karl, Holyoake, Tessa L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Zhang, Bin   +9 more
core   +1 more source

Emerging Therapeutic Strategies for Hearing Loss

Advanced Therapeutics, EarlyView.
Challenges still exist in treating hearing loss in cases of severe damage to hair cells or spiral ganglion neurons. Here, a schematic diagram of cochlear sensory hair cells and auditory nerves is presented. It is found that in normal Corti organs, hair cells have upright stereocilia at the top and auditory neurons at the base. Ototoxic drugs, noise, or
Shanying Han, Tian Shen, Weiwei He, Hao Wei, Xiaolong Zhao, Wen Yang, Chuan Bu, Xinghua Tang, Yu Zhao, Jiangang Fan   +9 more
wiley   +1 more source

Tocilizumab versus anakinra in COVID-19: results from propensity score matching

Frontiers in Immunology, 2023
BackgroundTocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the efficacy of tocilizumab versus anakinra to guide the choice of the therapy ...
Robin Arcani, Robin Arcani, Florian Correard, Pierre Suchon, Gilles Kaplanski, Gilles Kaplanski, Rodolphe Jean, Raphael Cauchois, Raphael Cauchois, Marine Leprince, Vincent Arcani, Julie Seguier, Benjamin De Sainte Marie, Baptiste Andre, Marie Koubi, Pascal Rossi, Stéphane Gayet, Nirvina Gobin, Victoria Garrido, Joris Weiland, Elisabeth Jouve, Anne-Laure Couderc, Anne-Laure Couderc, Patrick Villani, Patrick Villani, Aurélie Daumas, Aurélie Daumas   +26 more
doaj   +1 more source

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 beta inhibition [PDF]

, 2006
BACKGROUND:Neonatal-onset multisystem inflammatory disease is characterized by fever, urticarial rash, aseptic meningitis, deforming arthropathy, hearing loss, and mental retardation.
Adams, BS, Aksentijevich, I, Beitz, LO, Brewer, C, Butman, JA, Canna, SW, Cole, JL, Dailey, NJ, Fuhlbrigge, RC, Gardner, G, Gelabert, A, Goldbach-Mansky, R, Hannan, WP, Haverkamp, MH, Hawkins, PN, Hill, S, Hoffmann, SC, Holland, SM, Horn, W, Jarvis, JN, Jones, J, Karp, BI, Kastner, DL, Kim, HJ, Moore, TL, O'Neil, K, Paul, SM, Penzak, SR, Pham, TH, Pucino, F, Rubin, BI, Shaham, B, Snyder, C, Stein, L, Turner, ML, Vehe, RK, Warren, RW, Wesley, RA, Wiggs, E, Zalewski, C   +39 more
core  

Rational Design of Inner Ear Drug Delivery Systems

Advanced Science, EarlyView.
Hearing loss is a common disease affecting many people, and inner ear lesions are one of the most important causes. This review focuses on the treatment of inner ear hearing loss by drug delivery systems. It includes the current methods and technologies developed, and it predicts possible directions.
Xiayidan Maimaitikelimu, Zhiyan Xuan, Haoyu Ren, Keng Chen, Hui Zhang, Huan Wang   +5 more
wiley   +1 more source

A case of corticosteroid-dependent recurrent pericarditis with different response to two IL-1 blocking agents [PDF]

, 2015
Background: Recurrent pericarditis (RP) represents the most troublesome presentation of pericarditis and has a controversial pathogenesis that crosses infectious, auto-immune and auto-inflammatory pathways.
A von Scheven-Gête, F Angelini, K Theodoropoulou, M Hofer, M Prsa, S Bressieux-Degueldre, T Boulos   +6 more
core   +2 more sources